The exploratory study to determine the optimal initial dose of tyrosine kinase inhibitors including combination immunotherapy in individual patients with advanced renal cell carcinoma

The exploratory study to determine the optimal initial dose of tyrosine kinase inhibitors including combination immunotherapy in individual patients with advanced renal cell carcinoma - To determine the optimal initial dose of tyrosine kinase inhibitors including combination immunotherapy in renal cell carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040923

Enrollment

100

Registered

2020-07-01

Start date

2020-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal cell carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with advanced renal cell carcinoma treated with axitinib or cabozantinib

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
pharmacokinetic data, gene polymorphism, clinical efficacy, adverse events	—

Countries

Japan

Contacts

Public ContactYoshiaki Yamamoto

Graduate School of Medicine, Yamaguchi University Department of Urology

yoshiy@yamaguchi-u.ac.jp0836-22-2275

Outcome results